We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.08 | 0.08% | 97.21 | 97.35 | 96.715 | 96.97 | 95,058 | 15:01:16 |
From May 2021 to May 2024
By Cristina Roca
Novartis AG said late Wednesday that the U.S. Food and Drug Administration has approved Leqvio, a cholesterol therapy.
The Swiss pharmaceutical major said the treatment is the first and only small interfering RNA therapy to lower low-density lipoprotein cholesterol--also known as bad cholesterol--with two doses a year, delivered by injection.
"This approach may help those who have trouble sticking to medicines that are self-administered and have greater dosing frequency," the company said.
Leqvio will be available in early January, it said.
Novartis has acquired global rights to develop, manufacture and commercialize the drug under an agreement with Alnylam Pharmaceuticals Inc.
Write to Cristina Roca at cristina.roca@wsj.com
(END) Dow Jones Newswires
December 23, 2021 02:11 ET (07:11 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
